Public Employees Retirement Association of Colorado trimmed its stake in shares of Zoetis Inc (NYSE:ZTS) by 0.1% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,518,487 shares of the company’s stock after selling 1,584 shares during the quarter. Zoetis accounts for about 1.2% of Public Employees Retirement Association of Colorado’s holdings, making the stock its 17th largest position. Public Employees Retirement Association of Colorado owned about 0.32% of Zoetis worth $189,188,000 as of its most recent filing with the SEC.
Several other large investors also recently added to or reduced their stakes in ZTS. JJJ Advisors Inc. bought a new position in Zoetis during the 2nd quarter valued at approximately $25,000. Prestige Wealth Management Group LLC bought a new position in Zoetis in the 2nd quarter worth $27,000. Tarbox Family Office Inc. raised its holdings in Zoetis by 74.4% in the 3rd quarter. Tarbox Family Office Inc. now owns 218 shares of the company’s stock worth $27,000 after purchasing an additional 93 shares during the period. Altshuler Shaham Ltd raised its holdings in Zoetis by 198.8% in the 2nd quarter. Altshuler Shaham Ltd now owns 254 shares of the company’s stock worth $29,000 after purchasing an additional 169 shares during the period. Finally, Tradewinds Capital Management LLC bought a new position in Zoetis in the 3rd quarter worth $31,000. Institutional investors own 89.95% of the company’s stock.
In other news, EVP Clinton A. Jr. Lewis sold 6,123 shares of Zoetis stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $128.62, for a total value of $787,540.26. Following the sale, the executive vice president now directly owns 39,141 shares of the company’s stock, valued at $5,034,315.42. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Roxanne Lagano sold 4,463 shares of Zoetis stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $125.99, for a total value of $562,293.37. Following the completion of the sale, the executive vice president now directly owns 33,190 shares in the company, valued at $4,181,608.10. The disclosure for this sale can be found here. Over the last three months, insiders have sold 34,332 shares of company stock worth $4,258,182. Insiders own 0.29% of the company’s stock.
NYSE:ZTS traded down $3.17 on Friday, reaching $117.86. 3,757,845 shares of the company’s stock traded hands, compared to its average volume of 2,125,332. The company has a quick ratio of 2.87, a current ratio of 4.17 and a debt-to-equity ratio of 2.74. The stock has a 50-day simple moving average of $125.46 and a 200-day simple moving average of $116.48. The firm has a market cap of $57.43 billion, a PE ratio of 37.65, a P/E/G ratio of 2.98 and a beta of 0.88. Zoetis Inc has a 12 month low of $78.90 and a 12 month high of $130.20.
Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, November 7th. The company reported $0.94 EPS for the quarter, beating the Zacks’ consensus estimate of $0.88 by $0.06. The business had revenue of $1.58 billion for the quarter, compared to analysts’ expectations of $1.58 billion. Zoetis had a return on equity of 72.86% and a net margin of 22.74%. The business’s quarterly revenue was up 7.0% on a year-over-year basis. During the same period last year, the firm earned $0.83 earnings per share. On average, equities analysts anticipate that Zoetis Inc will post 3.57 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Tuesday, October 22nd will be issued a dividend of $0.164 per share. The ex-dividend date is Monday, October 21st. This represents a $0.66 dividend on an annualized basis and a yield of 0.56%. Zoetis’s dividend payout ratio is presently 21.09%.
A number of equities analysts recently commented on the company. Credit Suisse Group set a $138.00 target price on Zoetis and gave the stock a “buy” rating in a report on Friday, October 11th. Craig Hallum raised their target price on Zoetis from $132.00 to $138.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. Barclays raised their target price on Zoetis from $120.00 to $135.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. Morgan Stanley raised their target price on Zoetis from $100.00 to $136.00 and gave the stock an “equal weight” rating in a report on Monday, September 30th. Finally, ValuEngine cut Zoetis from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Eight research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. Zoetis presently has an average rating of “Buy” and a consensus price target of $126.75.
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Further Reading: What does the Dogs of the Dow mean?
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.